9 Meters Biopharma (NMTR) Competitors

Purple Biotech (NASDAQ:PPBT) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.

Do insiders and institutionals have more ownership in PPBT or NMTR?

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, PPBT or NMTR?

Purple Biotech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.

Which has higher valuation & earnings, PPBT or NMTR?

Purple Biotech is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$19.88M	-$8.79	-0.36
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Is PPBT or NMTR more profitable?

Purple Biotech's return on equity of -55.86% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-55.86%	-44.67%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Does the MarketBeat Community prefer PPBT or NMTR?

9 Meters Biopharma received 20 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 71.15% of users gave 9 Meters Biopharma an outperform vote.

Company	Underperform	Outperform
Purple Biotech	Outperform Votes 17 94.44%	Underperform Votes 1 5.56%
9 Meters Biopharma	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%

Does the media prefer PPBT or NMTR?

In the previous week, Purple Biotech had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 beat Purple Biotech's score of -0.88 indicating that 9 Meters Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Negative
9 Meters Biopharma	Neutral

Do analysts recommend PPBT or NMTR?

Purple Biotech currently has a consensus price target of $33.00, suggesting a potential upside of 941.01%. Given Purple Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Purple Biotech is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Purple Biotech beats 9 Meters Biopharma on 9 of the 15 factors compared between the two stocks.